Amylyx Pharmaceuticals Inc
NASDAQ:AMLX

Watchlist Manager
Amylyx Pharmaceuticals Inc Logo
Amylyx Pharmaceuticals Inc
NASDAQ:AMLX
Watchlist
Price: 12.56 USD -4.12%
Market Cap: 1.4B USD

Relative Value

There is not enough data to reliably calculate the relative value of AMLX.

Relative Value is the estimated value of a stock based on various valuation multiples like P/E and EV/EBIT ratios. It offers a quick snapshot of a stock's valuation in relation to its peers and historical norms.

AMLX Relative Value
Base Case
Not Available
Worst Case
Base Case
Best Case

Valuation Multiples

vs History
vs Industry
56
Median 3Y
3
Median 5Y
3.9
Industry
2.6
vs History
vs Industry
42
Median 3Y
-2.1
Median 5Y
-4.1
Industry
21.6
Forward
-7.8
vs History
vs Industry
39
Median 3Y
-4.2
Median 5Y
-7.3
Industry
16.5
vs History
vs Industry
30
Median 3Y
-3.4
Median 5Y
-7.2
Industry
22.5
vs History
36
vs Industry
44
Median 3Y
2.9
Median 5Y
3.1
Industry
2.3
vs History
vs Industry
85
Median 3Y
1.6
Median 5Y
2.7
Industry
2.9
vs History
vs Industry
86
Median 3Y
1
Median 5Y
-0.5
Industry
5.5
vs History
vs Industry
15
Median 3Y
-7.6
Median 5Y
-7.3
Industry
13
Forward
-6.4
vs History
vs Industry
18
Median 3Y
-7.5
Median 5Y
-7.3
Industry
16.6
Forward
-6.4
vs History
vs Industry
5
Median 3Y
-7.7
Median 5Y
-7.7
Industry
15.8
vs History
vs Industry
6
Median 3Y
-7.7
Median 5Y
-7.7
Industry
19.1
vs History
22
vs Industry
12
Median 3Y
15.3
Median 5Y
23.6
Industry
1.9

Multiples Across Competitors

AMLX Competitors Multiples
Amylyx Pharmaceuticals Inc Competitors

All Multiples
P/S
P/E
EV/EBITDA
EV/EBIT
All Countries
Close
Market Cap P/S P/E EV/EBITDA EV/EBIT
US
Amylyx Pharmaceuticals Inc
NASDAQ:AMLX
1.4B USD 0 -9.2 -6.6 -6.6
US
Eli Lilly and Co
NYSE:LLY
988.4B USD 16.7 54.1 36 38.6
UK
Dechra Pharmaceuticals PLC
LSE:DPH
440.4B GBP 578.3 -15 783.5 3 846.3 17 702.3
US
Johnson & Johnson
NYSE:JNJ
514B USD 5.6 20.4 16.7 21.7
CH
Roche Holding AG
SIX:ROG
255.9B CHF 4.2 27.1 11.6 13.5
UK
AstraZeneca PLC
LSE:AZN
209.3B GBP 4.8 29.8 108.2 158.3
CH
Novartis AG
SIX:NOVN
207B CHF 4.6 18.1 11.5 14.8
US
Merck & Co Inc
NYSE:MRK
242B USD 3.8 12.7 9.1 10.8
DK
Novo Nordisk A/S
CSE:NOVO B
1.4T DKK 4.4 13.4 9.4 10.9
IE
Endo International PLC
LSE:0Y5F
209B USD 90.1 -71.5 331.1 830.4
US
Pfizer Inc
NYSE:PFE
146B USD 2.3 14.8 7.5 10.3
P/E Multiple
Earnings Growth PEG
US
Amylyx Pharmaceuticals Inc
NASDAQ:AMLX
Average P/E: 23.8
Negative Multiple: -9.2
N/A N/A
US
Eli Lilly and Co
NYSE:LLY
54.1
53%
1
UK
Dechra Pharmaceuticals PLC
LSE:DPH
Negative Multiple: -15 783.5 N/A N/A
US
Johnson & Johnson
NYSE:JNJ
20.4
29%
0.7
CH
Roche Holding AG
SIX:ROG
27.1
29%
0.9
UK
AstraZeneca PLC
LSE:AZN
29.8
38%
0.8
CH
Novartis AG
SIX:NOVN
18.1
17%
1.1
US
Merck & Co Inc
NYSE:MRK
12.7
15%
0.8
DK
Novo Nordisk A/S
CSE:NOVO B
13.4
4%
3.4
IE
E
Endo International PLC
LSE:0Y5F
Negative Multiple: -71.5 N/A N/A
US
Pfizer Inc
NYSE:PFE
14.8
29%
0.5
EV/EBITDA Multiple
EBITDA Growth EV/EBITDA to Growth
US
Amylyx Pharmaceuticals Inc
NASDAQ:AMLX
Average EV/EBITDA: 438.7
Negative Multiple: -6.6
N/A N/A
US
Eli Lilly and Co
NYSE:LLY
36
33%
1.1
UK
Dechra Pharmaceuticals PLC
LSE:DPH
3 846.3
36%
106.8
US
Johnson & Johnson
NYSE:JNJ
16.7
9%
1.9
CH
Roche Holding AG
SIX:ROG
11.6
4%
2.9
UK
AstraZeneca PLC
LSE:AZN
108.2
10%
10.8
CH
Novartis AG
SIX:NOVN
11.5
6%
1.9
US
Merck & Co Inc
NYSE:MRK
9.1
6%
1.5
DK
Novo Nordisk A/S
CSE:NOVO B
9.4
2%
4.7
IE
E
Endo International PLC
LSE:0Y5F
331.1
N/A N/A
US
Pfizer Inc
NYSE:PFE
7.5
1%
7.5
EV/EBIT Multiple
EBIT Growth EV/EBIT to Growth
US
Amylyx Pharmaceuticals Inc
NASDAQ:AMLX
Average EV/EBIT: 1 881.2
Negative Multiple: -6.6
N/A N/A
US
Eli Lilly and Co
NYSE:LLY
38.6
36%
1.1
UK
Dechra Pharmaceuticals PLC
LSE:DPH
17 702.3
98%
180.6
US
Johnson & Johnson
NYSE:JNJ
21.7
15%
1.4
CH
Roche Holding AG
SIX:ROG
13.5
5%
2.7
UK
AstraZeneca PLC
LSE:AZN
158.3
23%
6.9
CH
Novartis AG
SIX:NOVN
14.8
12%
1.2
US
Merck & Co Inc
NYSE:MRK
10.8
8%
1.3
DK
Novo Nordisk A/S
CSE:NOVO B
10.9
1%
10.9
IE
E
Endo International PLC
LSE:0Y5F
830.4
N/A N/A
US
Pfizer Inc
NYSE:PFE
10.3
8%
1.3